The availability of essential medicines for public healthcare in low-income countries is very limited and patients have to buy drugs in the private sector at far higher prices, despite such countries'pharma spending accounting for 20–60% of healthcare budgets.
This percentage compares with 18% of healthcare budgets being spent on pharmaceuticals in countries of the Organisation for Economic Co-operation...






